Postmarketing non-interventional safety study on medicinal product Buprenorphine Actavis 35; 52,5; 70 microgram/h transdermal patch in Czech Republic, No.1303010000

First published: 13/01/2016

Last updated: 13/01/2016

Study Planned

Administrative details

EU PAS number

EUPAS12041

Study ID

12042

DARWIN EU® study

No

Study countries

Czechia

Study description

PASS searching and collecting reports on adverse drug reaction, possibility of follow-up of the development of the clinical status of a patient and analyze reports.

Study status

Planned

Research institutions and networks

Institutions

Actavis

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Eugenia Prochazkova eugenia.prochazkova@actavis.com

Study contact

eugenia.prochazkova@actavis.com

Primary lead investigator

Martin Pytlik

Primary lead investigator

Study timelines

Date when funding contract was signed
Planned: 13/02/2013

Study start date
Planned: 04/03/2013

Data analysis start date
Planned: 28/02/2016

Date of final study report
Planned: 31/12/2016

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Actavis

Regulatory

Was the study required by a regulatory body?

No

Methodological aspects

Study type

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Other

If ‘other’, further details on the scope of the study

Patient´s and treatment characteristics

Main study objective:

Obtaining information about safety of the drug and patient´s characterstics.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name, other

Buprenorphine Actavis 35, 52,5, 70 mikrogramů/h transdermální náplast

---

Study drug International non-proprietary name (INN) or common name

BUPRENORPHINE

Anatomical Therapeutic Chemical (ATC) code

(N02AE01) buprenorphine

buprenorphine

Population studied

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)

Estimated number of subjects

675

Study design details

Data analysis plan

Query investigation with statistical evaluation of results.

Data management

ENCePP Seal

> The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Administrative healthcare records (e.g., claims)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No